Chronic Lymphocytic Leukemia

Alexey Danilov, MD, PhD, provides an overview on the recent updates and research in the chronic lymphocytic leukemia space.

In an interview with Targeted Oncology, Brian T. Hill, MD, PhD, discussed making treatment decisions for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Alexey Danilov, MD, PhD, discusses some targeted therapies being investigated in the relapsed/refractory chronic lymphocytic leukemia space.

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.

William Wierda, MD, PhD, explored the emergence of small molecule-inhibitor targeted therapies during the “Workup of CLL in the Era of Small Molecules,” presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Alexey Danilov, MD, PhD, discusses the current treatment landscape for chronic lymphocytic leukemia and how it has evolved.

In an interview with Targeted Oncology, Alexey Danilov, MD, PhD, delved into the latest treatment strategies and approvals investigated for patients with chronic lymphocytic leukemia.

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.

The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome

Although there have been major advances in treating CLL, the disease remains incurable in most cases, so there is room for improvement,

During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.

Treatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.

Anthony Mato, MD, discusses the case of a 76-year-old man with stage IV chronic lymphocytic leukemia.

In an interview with Targeted Oncology following the tweet chat, Cyrus M. Khan, MD, discussed the emerging and recent data he thinks could influence the case we discussed.

A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.

Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.

Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.

Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.

Wojciech Jurczak, MD, PhD, discussed the results of the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.

In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.

Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.

Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.

During a Targeted Oncology case-based roundtable event, John N. Allan, MD, discussed the factors for choosing treatment for chronic lymphocytic leukemia with a Bruton tyrosine kinase inhibitor.